Accelerating Bone Healing Through Targeted Nanotherapy
Apr 8, 2026 | 5 min read
“Nexocura has the potential to impact recovery for millions of fracture patients by giving them a non-surgical option to stimulate bone repair.”
Every year, more than 178 million fractures occur worldwide. While many heal with the surgical standard care, recovery is not guaranteed. Between 10–15% of patients experience delayed healing. In high-risk patients, including older adults and those with diabetes or obesity, that number can reach up to nearly 50% of fractures. In the United States alone, there are about 2.2 million fractures that heal poorly each year.
When bones fail to heal properly, the consequences can be severe: repeat surgeries, chronic pain, and long recovery periods that disrupt daily life. Despite the scale of this issue, there are currently no reliable, non-surgical drug treatments that effectively promote bone healing. Nexocura, a translational project based at UCSF, is working to change that.
A New Approach to Bone Repair
Nexocura is developing a novel, non-surgical treatment designed to help bones heal faster and more effectively. Delivered through a single injection at the injury site, the treatment uses a protein-coding nanotherapeutic that instructs cells to produce β-catenin, a key protein involved in the body’s natural healing program, the Wnt pathway.
This Wnt pathway plays a critical role in bone formation and repair. By activating it locally at the fracture site, Nexocura’s approach enables the body to rebuild bone more effectively. Rather than relying on external implants or invasive surgeries, this approach works with the body’s own biology to promote healing.
How Nexocura Stands Out
The treatment options currently available for bone fracture are limited and often invasive. Bone morphogenetic proteins (BMPs), for example, require surgical implantation, are expensive, and can produce inconsistent results alongside a risk for serious side effects. Other therapies, such as parathyroid drugs like FORTEO® and TYMLOS®, are approved for osteoporosis but have not shown strong evidence for improving fracture healing. EVENITY®, a more recent drug targeting the same Wnt biological pathway, has also only been effective for osteoporosis and did not demonstrate meaningful results in fracture repair possibly due to the incorrect timing or low localized activation of this key pathway.
Nexocura is designed to overcome these limitations with a more targeted and accessible solution. It delivers treatment directly to the injury site with a single, non-surgical injection, making it far less invasive than surgical options. By activating the body’s natural bone-healing process more precisely, it has the potential to be more effective than existing therapies. It is also being developed with the goal of having an accessible price point and decreasing the risk of fracture non-union which was estimated to cost $130,000 per patient in 2025.
Collaboration with the Master of Translational Medicine (MTM) Program
MTM students play a key role in advancing Nexocura. They are actively involved in developing a comprehensive commercialization strategy, which includes speaking with key opinion leaders to optimize the target clinical indication, evaluating potential revenue models, identifying market opportunities, and exploring exit strategies.
In addition, the team has defined a regulatory pathway and a plan to obtain the key safety data to support an FDA interact meeting.
The MTM students have been very important in obtaining grant funding and refining a pitch deck to support investor interest. The MTM team successfully received a HIVE (Healthcare Innovation via Engineering, https://engineering.ucsf.edu ) Pilot Grant for $25,000 and a UCSF Catalyst Award culminating in a pitch deck that they helped to curate. The clear commercialization plan they have helped develop is the critical first step to moving this exciting technology out of the laboratory and into thoughtfully designed clinical trials that have a real potential to improve patient outcomes following fracture.
The Vision Behind Nexocura
Professor Chelsea Bahney, the project’s capstone sponsor, is a researcher and serial entrepreneur at UCSF, where she leads the Laboratory for Regenerative Therapeutics in the Department of Orthopaedic Surgery. Her work focuses on developing new therapies and diagnostics that improve patient outcomes
Professor Bahney has years of experience translating scientific discoveries into real-world solutions. “I love working with the MTM students and supporting this amazing joint UCSF/UC Berkeley program! They are incredibly bright and motivated and have been a true catalyst in receiving millions of dollars in non-dilutive funding to support bench to bedside translation of two different products,” she explained. She is passionate about developing better solutions for patients using great science–helping people heal faster and avoid the challenges of prolonged recovery and repeat surgeries.
For those interested in learning more about Nexocura or collaborating on this initiative, Dr. Bahney’s team is based in San Francisco at UCSF Department of Orthopedic Surgery. Readers interested in learning more or exploring collaborations can reach the team through: Chelsea Bahney, PhD – UCSF (Email: chelsea.bahney@ucsf.edu; Linkedin: linkedin.com/in/chelsea-bahney-91a9302)
Nexocura’s work builds on promising preclinical studies demonstrating accelerated fracture healing in animal models. The study has been published, demonstrating the potential of their approach. You can read their publications here:
β-catenin mRNA encapsulated in SM-102 lipid nanoparticles enhances bone formation in a murine tibia fracture repair model (DOI: 10.1016/j.bioactmat.2024.05.020)
Efficacy of biomarkers in the endochondral phase of fracture repair and healing in long bones: A clinical observational study. (https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004640)
With its innovative approach, Nexocura is redefining what recovery can look like. By reducing the need for invasive procedures, this project enables faster, more reliable healing. Nexocura has the potential to impact millions of patients and reshape the future of orthopaedic care.